Abstract
The progesterone receptor (PR) is a ligand-activated steroid receptor in the nuclear receptor (NR) superfamily of transcription factor. Besides gynecological and obstetrical indications, the involvement/mechanism of PR in many other diseases, such as oncology, neurology, immunology, etc. has been revealed and studied in recent decades. Therapeutic agents that selectively activate or inhibit PR have been developed. PR agonists have generally been used in oral contraception and postmenopausal hormone replacement therapy (HRT), typically in combination with estrogens. PR antagonists and selective PR modulators (SPRMs) can be useful therapies for hormone dependent breast and prostate cancers, nonmalignant chronic conditions such as fibroids, and endometriosis. This review provides an overview and detailed discussions about the recent development of chemical structures of the PR ligands, their structural characteristics (particularly those contributing to their activity and selectivity), in vitro/in vivo studies and clinical trial outcomes, and the synthetic methodologies.
Keywords: Agonist, Antagonist, Ligand, Modulator, Nonsteroid, Progesterone receptor, Steroid.
Current Medicinal Chemistry
Title:Current Progresses and Trends in the Development of Progesterone Receptor Modulators
Volume: 23 Issue: 23
Author(s): Wenlu Li, Xi Li, Bin Zhang, Chunmei Gao, Yuzong Chen and Yuyang Jiang
Affiliation:
Keywords: Agonist, Antagonist, Ligand, Modulator, Nonsteroid, Progesterone receptor, Steroid.
Abstract: The progesterone receptor (PR) is a ligand-activated steroid receptor in the nuclear receptor (NR) superfamily of transcription factor. Besides gynecological and obstetrical indications, the involvement/mechanism of PR in many other diseases, such as oncology, neurology, immunology, etc. has been revealed and studied in recent decades. Therapeutic agents that selectively activate or inhibit PR have been developed. PR agonists have generally been used in oral contraception and postmenopausal hormone replacement therapy (HRT), typically in combination with estrogens. PR antagonists and selective PR modulators (SPRMs) can be useful therapies for hormone dependent breast and prostate cancers, nonmalignant chronic conditions such as fibroids, and endometriosis. This review provides an overview and detailed discussions about the recent development of chemical structures of the PR ligands, their structural characteristics (particularly those contributing to their activity and selectivity), in vitro/in vivo studies and clinical trial outcomes, and the synthetic methodologies.
Export Options
About this article
Cite this article as:
Li Wenlu, Li Xi, Zhang Bin, Gao Chunmei, Chen Yuzong and Jiang Yuyang, Current Progresses and Trends in the Development of Progesterone Receptor Modulators, Current Medicinal Chemistry 2016; 23 (23) . https://dx.doi.org/10.2174/0929867323666160428105310
DOI https://dx.doi.org/10.2174/0929867323666160428105310 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Repurposing Chloroquine Analogs as an Adjuvant Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Relevance of Multidrug Resistance Proteins on the Clinical Efficacy of Cancer Therapy
Current Drug Delivery Subject Index Volume 6
Mini-Reviews in Medicinal Chemistry Targeting Kinase Interaction Networks: A New Paradigm in PPI Based Design of Kinase Inhibitors
Current Topics in Medicinal Chemistry Development of Molecular Targeted Anticancer Agents: Successes, Failures and Future Directions
Current Pharmaceutical Design Cytotoxicity and Molecular Targeting Study of Novel 2-Chloro-3- substituted Quinoline Derivatives as Antitumor Agents
Letters in Drug Design & Discovery The Role of Melanocortin Peptides and Receptors in Regulation of Energy Balance
Current Pharmaceutical Design Engineered Inorganic/Organic-Core/Shell Magnetic Fe<sub>x</sub>O<sub>y</sub> Nanoparticles with Oleic Acid and/or Oleylamine As Capping Agents
Current Pharmaceutical Design Neurorestorative Role of Stem Cells in Alzheimer’s Disease: Astrocyte Involvement
Current Alzheimer Research Advances in Tumor Targeted Liposomes
Current Molecular Medicine Cancer Preventive Effects of Vitamin E
Current Pharmaceutical Biotechnology Diagnostic and Therapeutic Use of Human Recombinant Thyrotropin (rhTSH)(Thyrogen®) in Well-Differentiated Thyroid Cancer - Current Indications and Future Perspectives - A Review
Current Pharmaceutical Analysis Saponins in Tumor Therapy
Mini-Reviews in Medicinal Chemistry Pharmacometrics of Stilbenes: Seguing Towards the Clinic
Current Clinical Pharmacology In silico Methods for Designing Antagonists to Anti-apoptotic Members of Bcl-2 Family Proteins
Mini-Reviews in Medicinal Chemistry Chemopreventive Agents Alters Global Gene Expression Pattern: Predicting their Mode of Action and Targets
Current Cancer Drug Targets An Expanding Appreciation of the Role Chemokine Receptors Play in Cancer Progression
Current Pharmaceutical Design Pharmacological Inhibition of the Bcl-2 Family of Apoptosis Regulators as Cancer Therapy
Current Molecular Pharmacology LRP/LR as an Alternative Promising Target in Therapy of Prion Diseases, Alzheimers Disease and Cancer
Infectious Disorders - Drug Targets Kisspeptin: Paving the Way to a New Therapeutic Avenue in Reproduction
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery